CRSP CRISPR Therapeutics AG
8-K Current Report
Filed: March 16, 2026
Health Care
Biological Products, (No Diagnostic Substances)CRISPR Therapeutics AG (CRSP) 8-K current report filed with SEC EDGAR on March 16, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 1.01: Entry into a Material Definitive Agreement
AI Filing Analysis8-K
Item 1.01 · Entry into a Material Definitive Agreement
- • Convertible notes sold via Rule 144A private placement to qualified institutional buyers — no public registration, limiting secondary market liquidity
- • Purchase agreement dated March 10, 2026 between CRISPR Therapeutics and initial purchasers — conversion into common shares exempt under Securities Act Section 3(a)(9)
Other CRISPR Therapeutics AG 8-K Filings
Get deeper insights on CRISPR Therapeutics AG
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.